1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Disease Analysis & Statistics 2021 - Northern Europe

Chronic Disease Analysis & Statistics 2021 - Northern Europe

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence

All regions

  • All
    • Europe
      • Northern Europe
1-11 of 11 reports

Drug Delivery: Inhalation Devices

  • $ 4750
  • October 2019
  • 47 pages

Overview In 2018, combined sales of inhaled asthma and COPD devices in the countries covered by this analysis totaled approximately $10.4bn. Over the forecast period covered by this analysis, total sales ...

  • World
  • Spain
  • Asthma
  • Drug Delivery
  • Industry analysis
  • Asthma Prevalence

Market Spotlight: Fibromyalgia

  • $ 1318
  • March 2021
  • 37 pages

This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability ...

  • World
  • Europe
  • Chronic Pain
  • Clinical Trial
  • Industry analysis
  • Drug Approval

Anemia in Chronic Kidney Disease KOL Interview – US, East Coast

  • $ 599
  • June 2020
  • 16 pages

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications ...

  • United Kingdom
  • United States
  • Renal Cancer
  • Chronic Disease
  • Industry analysis

Type 1 Diabetes KOL Interview – UK

  • $ 599
  • January 2020
  • 13 pages

This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market, the unmet needs in type 1 diabetes, ...

  • United Kingdom
  • Type 1 Diabetes
  • Industry analysis

Rheumatoid Arthritis Payer Interview – UK

  • $ 599
  • August 2019
  • 18 pages

Overview A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

  • United Kingdom
  • Arthritis
  • Industry analysis

Rheumatoid Arthritis KOL Interview – UK

  • $ 599
  • July 2019
  • 14 pages

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies fo ...

  • United Kingdom
  • Arthritis
  • Industry analysis

Datamonitor Healthcare Chronic Heart Failure KOL Interview – UK

  • $ 599
  • February 2019
  • 12 pages

Overview A UK KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlano ...

  • United Kingdom
  • Cardiovascular Disease
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Industry analysis

Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK

  • $ 599
  • October 2018
  • 11 pages

Overview In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients. ...

  • United Kingdom
  • Type 2 Diabetes
  • Industry analysis

Opsumit

  • $ 10000
  • October 2018
  • 19 pages

Drug Overview Originally developed by Actelion, Johnson and Johnson’s Opsumit (macitentan) is the follow-on product to the leading pulmonary hypertension therapy Tracleer. The drug is a next-generation ...

  • Spain
  • France
  • Respiratory Treatment
  • Hypertension
  • Industry analysis

Breo Ellipta

  • $ 10000
  • July 2018
  • 41 pages

Drug Overview Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Fluticasone ...

  • Japan
  • Germany
  • Respiratory Disease
  • Hormone
  • Industry analysis

Advair

  • $ 10000
  • July 2018
  • 37 pages

Drug Overview Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). ...

  • Europe
  • Japan
  • Pulmonary Delivery
  • Asthma
  • Industry analysis


About 4200 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Respiratory Disease Demographic Impact in Wales (UK)

  • October 2021
  • 9 pages
  • Wales
  • Influenza
  • Respiratory Disease
  • Industry analysis
  • Vaccination Coverage
  • Influenza Prevalence

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on